Article Information
History
- February 1, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Ryan Marsha,
- Claudio Dos Santosb,
- Alexander Yulec,d,
- Neele S Dellschafte,
- Caroline L Hoade,
- Christabella Ngc,d,
- Giles Majorc,f,
- Alan R Smythc,d,g,
- Damian Rivettb,* and
- Christopher van der Gasta,h,*
- aDepartment of Applied Sciences, Northumbria University, Newcastle, UK
- bDepartment of Natural Sciences, Manchester Metropolitan University, UK
- cSchool of Medicine, University of Nottingham, UK
- dNIHR Nottingham Biomedical Research Centre, UK
- eSir Peter Mansfield Imaging Centre, University of Nottingham, UK
- fNestlé Institute of Health Sciences, Société des Produits Nestlé, Lausanne, Switzerland
- gSchool of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, UK
- hDepartment of Respiratory Medicine, Northern Care Alliance NHS Foundation Trust, Salford, UK
- ↵*Correspondence to: Professor Chris van der Gast, Department of Applied Sciences, Ellison Building, Newcastle upon Tyne, NE1 8ST, UK; chris.vandergast{at}northumbria.ac.uk, Dr Damian Rivett, Department of Natural Sciences, John Dalton Building, Chester Street, Manchester, M1 5GD, UK; D.Rivett{at}mmu.ac.uk
Posted February 01, 2024.
Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis
